ANTISECRETORY ACTIVITY OF ESOMEPRAZOLE (EMANERA®) IN PATIENTS WITH ACID-DEPENDENT DISEASES

Download full text PDF
Issue: 
8
Year: 
2015

Professor S. Kurilovich (1,2), MD; E. Chekalina (1); A. Belkovets (1); L. Shcherbakova (1) 1 -Resarch Institute of Therapy and Preventive Medicine, Novosibirsk 2 -Novosibirsk State Medical University

The paper shows the high antisecretory potential of the esomeprazole generic drug Emanera® (KRKA) in patients with acid-related diseases (ulcer disease and erosive gastroduodenitis) during long-term (48-hour) monitoring of intragastric pH. No cases of primary resistance have been found. Conclusion. Emanera® at a dose of 40 mg is suitable for use in acid-related diseases including situation with high demands on the level of suppression of acidity (optimized Helicobacter Pylori eradication, erosive GERD and Barrett's esophagus, extraesophageal manifestations of GERD, etc.).
Keywords: 
acid-dependent diseases
esomeprazole
ulcer disease
erosive gastroduodenitis
pH-monitoring
Emanera®

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Nikonov E.L., Bulgakov S.A., Alekseenko S.A. Antisekretornaja terapija kislotozavisimyh zabolevanij / M.: AMTN, 2004; 216 s.
  2. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report // Gut. – 2012; 61: 646–64.
  3. Linar E.Ju. Avtomaticheskaja registratsija kontsentratsii vodorodnyh ionov v zheludke // Voprosy kliniki i lechenija zlokachestvennyh novoobrazo-vanij (Riga). – 1959; 6: 239–46.
  4. Leja Ju.Ja. rN-metrija zheludka / L.: Meditsina, 1987; 144 s.
  5. Jakovlev G.A. Hlorserebrjanye rN-zondy. Razrabotka i issledovanie parametrov // Elektronnaja tehnika. Ser.: SVCh-tehnika. – 1995; 2 (466): 40–4
  6. Bashaeva R.G. Primenenie rN-zondov novogo pokolenija v klinicheskoj praktike // Ros. gastroenterol. zhurn. – 2000; 4: 84–6.
  7. Trifonov M.M. Vnutrizheludochnaja rN-metrija: klinicheskie metodiki i pribory // Zdravoohranenie i med. tehnika. – 2003; 4: 40–1.
  8. Savarino V., Mela G., Zentilin P. et al. Comparison of 24 pH control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer // Aliment. Pharmacol. Ther. – 1998; 12 (12): 1241–7.
  9. Gorshkov V.A. Problemnye aspekty funktsional'nogo issledovanija zheludka pri kislotozavisimyh zabolevanijah // Gastroenterologija. – 2003; 1: 33–7.
  10. Mahakova G.Ch., Dicheva T.D., Odintsova T.A. i dr. Sravnitel'naja harak teristika kislotopodavljajuschih preparatov putem provedenija farmakologi-cheskih prob pri intragastral'noj sutochnoj rN-metrii // Lechaschij vrach. – 1999; 6: 24–6.
  11. Il'chenko A.A., Selezneva E.Ja., Sil'vestrova S.Ju. rN-metrija v otsenke ingibitorov protonnoj pompy // Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. – 2004; 3: 78–83.
  12. Jamieson J., Stein H., DeMeester T. et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility // Am. J. Gastroenterol. – 1992; 87 (9): 1102–11.
  13. Kuz'mina A.Ju., Kurilovich S.A., Razsolov N.A. Sutochnoe monitorirova nie vnutripischevodnoj rN v diagnostike gastroezofageal'noj refljuksnoj bolezni // Funktsional'naja diagnostika. – 2006; 2: 87–92.
  14. Burget D., Chiverton S., Hunt R. Is there an optimal degree of acid suppression for healing of duodenal ulce? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. – 1990; 99: 345–51.
  15. Howden C., Burget D., Hunt R. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-esophageal reflux disease // Scand. J. Gastroenterol. – 1994; 201: 79–82.
  16. Scott D., Weeks D., Merkers K. et al. Life and death of Helicobacter Pylori // Gut. – 1998; 43 (Suppl. 1): 56–60.
  17. Scott D., Markus E., Wen I. et al. Gen expression in vivo shows that Helicobacter Pylori colonizes an acid niche in the gastric surface // Proc. Nat. Acad. Sci USA. – 2007; 104: 7235–40.
  18. Gotoh A., Akamatsu T., Shimisu T. et al. Additive effect of pronase on the 18. efficacy of eradication therapy against Helicobacter Pylori // Helicobacter. – 2001; 11: 341–8.
  19. Graham D., Fishbach L. Helicobacter Pylori treatment in era of increasing antibiotic resistance // Gut. – 2010; 10 (1136): 2–11.
  20. Kurilovich S.A., Reshetnikov O.V., Shlykova L.G. i dr. Sutochnoe monitorirovanie vnutrizheludochnogo rN: mesto v prakticheskoj i nauchnoj gastro-enterologii // Sib. zhurnal gastroenterol. i gepatol. – 1998; 1 (7): 313–4.
  21. Reshetnikov O.V., Kurilovich S.A., Shlykova L.G. Pochemu neobhodimo sutochnoe monitorirovanie rN? // Konsilium. – 1999; 4 (7): 37–40.
  22. Kurilovich S.A., Reshetnikov A.V., Chernoshejkina L.G. i dr. Ingibitory sekretsii soljanoj kisloty: sravnitel'noe issledovanie effektivnosti razovoj dozy. Mat. Vseross. nauch. konf. s mezhdunar. uchastiem «Fiziologija i patologija pischevarenija». Gelendzhik, 4–6 sentjabrja 2002, Krasnodar, 2002; s. 116–7.
  23. Kurilovich S.A., Chernoshejkina L.E., Shlykova L.G. Lansoprazol i blokada zheludochnoj sekretsii: est' li razlichija sredi generikov? // Klin. perspektivy gastroenterol., gepatol. – 2007; 3: 31–4.
  24. Kurilovich S.A., Chernoshejkina L.G. Antisekretornyj potentsial pantoprazola (Sanpraza) // EiKG. – 2008; 7: 119–22.
  25. Rohss K., Hasselgren G., Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease // Dig. Dis. Sci. – 2002; 47: 954–8.
  26. Rohss K. et al. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazol 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastrooesophageal reflux symptoms // Eur. J. Clin. Pharmacol. – 2004; 60 (8): 531–9.
  27. Molina-Infante J., Lucendo A., Angueira T. et al. Optimized empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study // Aliment. Pharmacol. Ther. – 2015; doi:10.1111/apt.13069
  28. Bioequivalence study report summary of randomized, open-label, 2-way crossover bioequivalence study of two esomeprazole 40 mg gastro-resistant dosage forms in healthy volunteers. Data on file, Krka, d.d., 2015.